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Background: Over 15 000 new oesophago-gastric cancers are diagnosed annually in the United Kingdom, with most being
advanced disease. We identified and quantified features of this cancer in primary care.
Methods: Case–control study using electronic primary-care records of the UK patients agedX40 years was performed. Cases with
primary oesophago-gastric cancer were matched to controls on age, sex and practice. Putative features of cancer were identified
in the year before diagnosis. Odds ratios (ORs) were calculated for these features using conditional logistic regression, and
positive predictive values (PPVs) were calculated.
Results: A total of 7471 cases and 32 877 controls were studied. Sixteen features were independently associated with oesophago-
gastric cancer (all Po0.001): dysphagia, OR 139 (95% confidence interval 112–173); reflux, 5.7 (4.8–6.8); abdominal pain, 2.6 (2.3–
3.0); epigastric pain, 8.8 (7.0–11.0); dyspepsia, 6 (5.1–7.1); nausea and/or vomiting, 4.9 (4.0–6.0); constipation, 1.5 (1.2–1.7); chest
pain, 1.6 (1.4–1.9); weight loss, 8.9 (7.1–11.2); thrombocytosis, 2.4 (2.0–2.9); low haemoglobin, 2.4 (2.1–2.7); low MCV, 5.2 (4.2–6.4);
high inflammatory markers, 1.7 (1.4–2.0); raised hepatic enzymes, 1.3 (1.2–1.5); high white cell count, 1.4 (1.2–1.7); and high
cholesterol, 0.8 (0.7–0.8). The only PPV45% in patients X55 years was for dysphagia. In patients o55 years, all PPVs were o1%.
Conclusion: Symptoms of oesophago-gastric cancer reported in secondary care were also important in primary care. The results
should inform guidance and commissioning policy for upper GI endoscopy.
Oesophago-gastric tumours account for 6% of all UK cancers, with
15 500 new diagnoses each year (8173 oesophageal cancer; 7610
gastric cancer); two-thirds are in men, and 92% of new cases occur
in those aged X55 years (Office for National Statistics, 2010).
Worldwide, there are almost 1.5 million new cases annually, two-
thirds gastric and one-third oesophageal. In Western countries,
gastric cancer is decreasing in incidence, but the increase in
oesophageal cancer outweighs this fall, leading to an overall
increase (NHS Information Centre, 2010). Mortality is very high,
with 5-year survival, approximately 7% for oesophageal and 12%
for gastric cancers (Rachet et al, 2009).
There are presently no screening tests available for oesophago-
gastric cancer, other than surveillance of patients with Barrett’s
oesophagus, though this accounts foro5% of all new oesophageal
cancer diagnoses (Hvid-Jensen et al, 2011). Therefore, diagnosis
largely depends upon presentation with symptoms, generally to
primary care (Hamilton, 2010). However, symptoms are often
vague and are also common in benign conditions. Indeed,
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dyspepsia is experienced by 40% of the population, though only 5%
report it to their doctor (National Prescribing Centre, 2006).
Furthermore, treatment of dyspepsia with acid suppressants may
hide symptoms of gastric cancer and delay diagnosis (Talley et al,
1993). In the United Kingdom, selection of patients for investiga-
tion is guided by publications from the National Institute for
Health and Clinical Excellence (NICE) (NICE, 2004, 2005). These
recommendations were based almost entirely upon secondary-care
studies (that is, the referred population), and describe several
‘alarm’ symptoms (Meineche-Schmidt and Jorgensen, 2002;
Varadarajulu et al, 2005; Vakil et al, 2006). Even so, the yield of
upper gastrointestinal cancer with alarm symptoms is only 4%,
many of these cancers being at an advanced stage (Kapoor et al,
2005). Liberalising access to endoscopy in an attempt to increase
the number of early-stage cancers is an option, but this strategy
could increase the number of endoscopies up to 10-fold, with no
increase in the number of cancers diagnosed (Agreus et al, 2001).
In addition, public awareness of dysphagia as an alarm
symptom for oesophageal cancer is poor and may contribute to
patient delay in seeking advice (Tentzeris et al, 2011). An
awareness campaign for the United Kingdom is currently under
consideration. Thus, it is timely to study the features of oesophago-
gastric cancer as presented to primary care. It is also logical to
study the two cancer sites collectively, as they share a common
diagnostic test – endoscopy. The aim of this study was to identify
and quantify the clinical features of oesophago-gastric cancer in
primary care, ultimately to improve selection of patients for
investigation.
MATERIALS AND METHODS
This was a case–control study using data from the General Practice
Research Database (GPRD) in the United Kingdom. The GPRD
maintains an anonymised copy of medical records of participating
practices; these contain full details of the patient, including all
consultations, recorded symptoms, investigations and diagnoses.
The data are subject to stringent checks on validation and quality,
and they are regarded as high quality in terms of accuracy,
completeness and validity of diagnoses (Khan et al, 2010). We have
previously used similar methods for several cancer diagnostic
studies (Hamilton and Kernick, 2007; Dommett et al, 2012).
Identification of cases and controls. A list of 42 (18 oesophageal,
24 gastric) tumour diagnostic codes (available from the authors)
was collated from the GPRD master code library. This has
approximately 100 000 codes covering all events in primary
care. GPRD staff identified all patients X40 years with an
oesophago-gastric tumour diagnosed between 1 January 2000
and 31 December 2009, and with at least 1 year of data meeting
their quality standards before diagnosis. For each case, the GPRD
identified up to five controls, matched by year of birth, sex and
practice, using a computer-generated random sequence. We
excluded cases and controls with no consultations in the year
before diagnosis of the case (the index date). We included primary
oesophago-gastric cancers that had metastasised but excluded
cancers from other sites that had spread to the oesophagus or
stomach. Controls were excluded if they had ever had oesophago-
gastric cancer.
Selection of possible features of oesophago-gastric cancer. We
studied all previously described diagnostic features of oesophago-
gastric cancer identified in a literature review, supplemented by
literature from relevant cancer websites. The GPRD’s code list has
many synonyms for similar symptoms, often including additional
description such as severity or duration. These synonyms were
identified and merged. The dyspepsia variable merged codes with
either the word ‘dyspepsia’ or ‘indigestion’; the reflux variable
included ‘regurgitation’ as well as ‘reflux’; the variable ‘epigastric
pain’ required a precise anatomical description, whereas the
variable ‘abdominal pain’ incorporated all other abdominal pain
variables without a precise anatomical description. Occurrences of
features in the year before the index date were identified. These
were only retained if they occurred in X5% of cases or controls.
For laboratory tests, we used the local laboratory range to identify
abnormal results; we considered patients without a test to be
equivalent to those with a normal result. We merged all hepatic
enzyme results into a composite variable, deemed abnormal if any
enzyme was raised; similarly, abnormal erythrocyte sedimentation
rate, plasma viscosity and C-reactive protein were collated into a
single variable called raised inflammatory markers. To test for any
recording bias between cases and controls, we also identified all
codes for fractures (making the assumption that the fracture rate
would be approximately equal).
Analysis. All analyses were performed using Stata (version 11)
(Statacorp, 2010), and our main analytical method was conditional
logistic regression. Variables associated with oesophago-gastric
cancer with a P-value o0.1 in the univariable regressions entered
multivariable analyses. Multivariable regressions were performed
in stages, initially collecting similar variables together, such as
those reflecting abdominal pain. Significant variables then entered
a second stage, grouping variables into abdominal symptoms, other
symptoms and investigations. For these two stages, a threshold
P-value of o0.05 was used. The final model was derived from all
variables surviving the earlier staged regressions, and used a
threshold P-value of o0.01. All rejected variables were checked to
see if they contributed to the final model, and 11 clinically plausible
interactions were investigated. Stratified analyses were performed
as an exploratory analysis of the timing of symptoms. We also
examined the possibility that the symptom patterns differed
between oesophageal and gastric cancers by repeating the two
multivariable models in the single sites: where the odds ratios
(ORs) for features differed materially, an interaction term between
the symptom and cancer site was added to the final model.
Calculation of positive predictive values (PPVs). We calculated
PPVs for the risk of oesophago-gastric cancer in patients
consulting in primary care using Bayes’ theorem (Knottnerus
2002). In this, the posterior odds of disease¼ the prior odds the
likelihood ratio. For the prior odds, we used the age-specific
national incidence rate of oesophago-gastric cancer for 2008
(Cancer Research UK 2008). As all the 7471 cases analysed had
consulted in primary care, but only 32 877 of 36 212 (90.8%)
controls had consulted in the study period, we divided the
posterior odds by 0.908 to give predictive values for the consulting
population. This analysis was performed in two age groups over
and under 55 years to mirror the current UK national guidance
(NICE, 2004, 2005).
RESULTS
We were initially supplied with 7657 cases and 37 699 controls: this
includes 2968 cases in whom fewer than five controls were
available. The application of exclusions is shown in Figure 1.
The demographic features of patients are shown in Table 1, and
their clinical features are shown in Table 2. In the year before
diagnosis, cases presented to primary care more frequently than
controls: median number of consultations 26 (interquartile range
15–42) vs 15 (7–28); Po0.001 in Mann–Whitney test. For the
cases and controls, respectively, 130 (1.7%) and 521 (1.6%) had a
record of a fracture. Barrett’s oesophagus was recorded in 209
(2.8%) of cases, and 51 (0.2%) of controls.
Multivariable analysis results are shown in Table 3: of cases,
only 26.6% had none of the features present in this Table. Sixteen
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Figure 1. Application of exclusion criteria for cases and matched controls.
Table 1. Characteristics of patients in primary care with oesophago-gastric cancer and matched controls. Figures are in numbers (percentages)
Oesophageal cancer Gastric cancer
Cases
Controls
n¼21506 Cases
Controls
n¼11371
Age in
years
Total
n¼4854
Females
(n¼1680)
Males
(n¼3174)
Total
(n¼2617)
Females
(n¼992)
Males
(n¼1625)
40–54 387 (8.0) 94(5.6) 291 (9.2) 1539 (7.2) 130 (5.0) 49 (4.9) 80 (4.9) 497 (4.4)
55–69 1712 (35.2) 468 (27.9) 1243 (39.1) 7473 (34.8) 671 (25.6) 218 (22) 453 (27.9) 2887 (25.4)
70–84 2230 (45.9) 814 (48.5) 1416 (44.6) 10296 (47.9) 1437 (54.9) 523 (52.7) 914 (56.2) 6431 (56.6)
X85 532 (10.9) 304 (18.1) 224 (7.1) 2198 (10.2) 382 (14.6) 202 (20.4) 178 (11.0) 1556 (13.7)
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features were associated with oesophago-gastric cancer: all P-value
o0.001. No interaction terms with age or sex were found, but
interactions with dysphagia with loss of weight and dysphagia with
nausea and/or vomiting were antagonistic. The only symptom with
a markedly different OR between the two separate cancer sites was
dysphagia (oesophageal cancer, OR 230 (confidence interval (CI)
180–300); gastric cancer, OR 20 (CI 14–29)). When expressed as
an interaction term in the unified model, the interaction OR for
dysphagia was 0.27 (CI 0.21–0.33): Po0.001. The ORs for the
remaining symptoms were remarkably similar.
Stratified analyses were performed at 3, 6 and 9 months before
diagnosis on the final multivariable model. No differences between
the models were found at 3 and 6 months before diagnosis. Three
symptoms, dysphagia, dyspepsia and nausea and/or vomiting, were
associated with cancer at 9 months before diagnosis, ORs 120 (CI
15–980), 5.5 (CI 2.3–13) and 3.7 (CI 1.5–9), respectively.
Figure 2 shows PPVs for oesophago-gastric cancer for the
symptoms in Table 3, plus low haemoglobin and thrombocytosis
for patients aged X55 years. All PPVs for symptom combin-
ations in patients aged o55 years were o1% (data not shown).
The highest PPV in this age group was for dysphagia, 0.8%
(CI 0.4–1.5%).
DISCUSSION
This is the first study quantifying the risk of oesophago-gastric
cancer in primary care that incorporates single and multiple
symptoms, as well as laboratory results. Most of the symptoms that
have been reported from secondary-care studies and from patient
groups were also strongly associated with oesophago-gastric cancer
in this primary-care study. This was particularly so for dysphagia,
with a risk of cancer of 4.8%. No other isolated symptom had a risk
41%, even when we restricted the analysis to patients 455 years
of age to match current guidance. In combination, however, several
symptom pairs carried higher risks, especially when one of the
symptoms was loss of weight. In contrast, no symptom in patients
o55 years had a risk 41%, even dysphagia. The features in the
multivariable analysis reflect the symptomatology that was
apparent for at least 6 months before diagnosis, and a small
subset of the associations was present for even longer than 9
months before diagnosis.
Strengths and limitations of the study. This study is large, and
uses primary care data. This is crucial: selection of patients for
investigation is performed by clinicians in primary care, so
primary-care data must be used to illuminate the selection process.
Table 2. Frequency of selected features in cases and controls in the whole study population
Clinical feature
Cases, n (%),
n¼7471
Controls, n (%),
n¼32877
Likelihood ratio
(95% CI)
PPV as a percentagea
(95% CI)
Symptoms
Dysphagia 2420 (32.4) 185 (0.6) 57.6 (49.7–66.7) 1.5 (1.3–1.8)
Dyspepsia 1294 (17.3) 764 (2.3) 7.5 (6.8–8.1) 0.2 (0.19–0.22)
Nausea or vomiting 979 (13.1) 637 (1.9) 6.8 (6.1–7.4) 0.18 (0.17–0.2)
Abdominal pain 905 (12.1) 1310 (4.0) 3.0 (2.8–3.3) 0.08 (0.08–0.09)
Reflux 842 (11.3) 513 (1.6) 7.2 (6.5–8.0) 0.19 (0.18–0.22)
Chest pain 727 (9.7) 1589 (4.8) 2.0 (1.9–2.2) 0.05 (0.05–0.06)
Epigastric pain 617 (8.3) 266 (0.8) 10.2 (8.9–11.8) 0.28 (0.24–0.32)
Loss of weight 615 (8.2) 276 (0.8) 9.8 (8.5–11.3) 0.26 (0.23–0.31)
Constipation 608 (8.1) 1073 (3.3) 2.5 (2.3–2.8) 0.07 (0.06–0.07)
Investigations
Low haemoglobin 2045 (27.4) 3353 (10.2) 2.7 (2.6–2.8) 0.07 (0.07–0.08)
Abnormal hepatic
enzymes
1272 (17.0) 3479 (10.6) 1.6 (1.5–1.7) 0.04 (0.04–0.05)
Raised inflammatory
markers
1010 (13.5) 1421 (4.3) 3.1 (2.9–3.4) 0.08 (0.08–0.09)
Raised cholesterol 920 (12.3) 5180 (15.8) 0.8 (0.7–0.8) 0.02 (0.02–0.02)
Abbreviations: CI¼ confidence interval; PPV¼positive predictive value.
aPPV in the consulting population.
Table 3. Multivariable analysis of the clinical features of oesophago-
gastric cancer
Variable Odds ratio (95% CI)
Symptoms
Dysphagia 139 (112–173)
Loss of weight 8.9 (7.1–11.2)
Epigastric pain 8.8 (7.0–11)
Dyspepsia 6.0 (5.1–7.1)
Reflux 5.7 (4.8–6.8)
Nausea or vomiting 4.9 (4.0–6.0)
Abdominal pain 2.6 (2.3–3.0)
Chest pain 1.6 (1.4–1.9)
Constipation 1.5 (1.2–1.7)
Investigations
Thrombocytosis 2.4 (2.0–2.9)
Low haemoglobin 2.4 (2.1–2.7)
Low mean red cell volume 5.2 (4.2–6.4)
Leucocytosis 1.4 (1.2–1.7)
Raised inflammatory markers 1.7 (1.4–2.0)
Abnormal hepatic enzymes 1.3 (1.2–1.5)
Raised cholesterol 0.8 (0.7–0.8)
Interaction terms
Dysphagia and loss of weight 0.2 (0.06–0.5)
Dysphagia and nausea or vomiting 0.1 (0.06–0.2)
Abbreviation: CI¼ confidence interval.
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The GPRD is considered by many to be the gold standard of
longitudinal patient databases from primary care. It has been used
in nearly 1000 research papers published in peer-reviewed journals,
and its validity has been well documented (Herrett et al, 2010;
Khan et al, 2010). The patient population in the database is also
broadly representative of the UK population. In addition,
laboratory results are transmitted directly to the database, allowing
us to use the local normal range to identify abnormal results, as
well as minimising transcription errors. A further strength was our
decision to study oesophageal and gastric cancers together; it was
logical to answer the question of what clinical features should
prompt consideration of endoscopy, as both cancers share the
same investigation. In any case, the associations between
symptoms and the individual cancers were remarkably similar
(other than for dysphagia). A previous primary-care study
agrees with this finding, suggesting that dysphagia should be
taken seriously as a warning of oesophageal malignancy (Jones
et al, 2009).
We could not check the accuracy of diagnosis in the cases by
histology or determine the staging. This is less important than it
appears: primary-care recording of cancer diagnoses is excellent,
especially because maintaining a cancer registry became one of the
items in the Quality and Outcomes Framework. Staging data may
have allowed us to identify clinical features, particularly associated
with early-stage cancer: although superficially attractive, it is
actually valuable to identify all cancers, including those that cannot
be cured, as treatment may still be beneficial.
The main limitation of the study is that we had to rely upon the
accurate recording by GPs of symptoms. Under-recording of
symptoms or signs may have led to some features that may be
genuinely associated with oesophago-gastric cancer not being
identified, such as upper gastrointestinal bleeding. When
calculating PPVs, under-recording is only important if the
proportion of symptom under-recording was markedly higher in
either cases or controls. We have no reason to believe this is the
case (Hamilton, 2009).
Comparison with existing literature. The prevalence of the
common symptoms of oesophago-gastric cancer in cases was
lower than in previous secondary-care studies (Ojala et al, 1982;
Bodger et al, 2000; Fransen et al, 2007; Berrill et al, 2011). This
probably reflects different symptom experience early in the disease,
especially in primary care. There are two possible alternative
explanations. The first is under-recording of symptoms as
discussed earlier, and the second is that most previous studies
directly interviewed patients after diagnosis. Such methods may be
subjected to recall bias, thus reporting higher rates of symptoms
than studies using indirect methods, such as ours. Again, this may
matter less than it appears: unvoiced symptoms are a well-
recognised feature of primary care, and can only be combated by
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Figure 2. PPVs (95% CIs) for oesophago-gastric cancer in men and women aged455 years for individual risk markers and for pairs of risk markers
in combination. The top figure in each cell is the PPV (95% CIs) when both features are present. CIs have not been calculated when any cell in the
22 table waso5 (invariably, this was because too few controls had both features). The yellow shading is for features with a PPV41%; the amber
for PPV42.0% and the red for PPV45.0%. The cells along the diagonal relate to the PPV when the same feature has been reported twice. Thus,
the dysphagia/dysphagia intersect is the PPV for oesophago-gastric cancer when a patient has attended at least twice with dysphagia.
Oesophago-gastric cancer diagnosis in primary care BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2012.551 29
using checklists, a procedure rarely used in primary care. The risk
from dysphagia in primary care has previously been estimated as
5.4% in men and 2.7% in women (Jones et al, 2007). Our figure of
4.8% (with little difference between the sexes) is similar. Another
primary-care study using a different data set has reported
associations for six features of cancer (dysphagia, haematemesis,
abdominal pain, loss of weight, loss of appetite and anaemia),
though without reporting PPVs (Hippisley-Cox and Coupland,
2011). Our finding of a strong association between a raised platelet
count and cancer has been described before for ovarian and lung
cancers, though not for oesophago-gastric tumours (Hamilton
et al, 2005; Stone et al, 2012).
Implications for clinical practice and future research. Selection
of patients for investigation – generally by endoscopy – has always
been difficult. The ‘alarm’ symptoms, such as loss of weight or
dysphagia, are shown in this study to have a sufficiently high PPV
to warrant endoscopy, though in the case of weight loss, additional
symptoms are needed to raise the PPV 41%. Our figures support
current NICE guidance on such symptoms (NICE, 2005).
However, using alarm symptoms alone to identify patients for
endoscopy will miss over half of patients with cancer, as only 32%
of our cases had reported dysphagia, and 8% reported loss of
weight. A previous primary-care study agrees with this,
suggesting that a symptom-based approach, focusing on single
symptoms, such as dysphagia, is likely to miss 40% of current
oesophago-gastric cancers, some of which will be at a curable stage
(Jones et al, 2007).
It has long been recognised that certain ‘low-risk but not no-
risk’ symptoms are associated with cancer – particularly dyspepsia.
The risk is even lower in younger patients, though the decision to
use a threshold age of 55 years for investigation was not based on
primary-care literature, and is hotly contested, especially by patient
advocacy groups. There is no generally agreed view of a particular
level of risk that warrants cancer investigation: patients, commis-
sioners of care and clinicians will all have a voice in such a
decision, which will need to include a health-economic dimension.
If a 2% risk is chosen, endoscopy would be offered to over 55
patients, for most patients with loss of weight and a second
gastrointestinal symptom, as well as all patients with dysphagia. It
is only if a lower figure of (say) 1% risk is accepted that a much
larger group of patients are selected for endoscopy. This would
include most combinations of dyspepsia with a second symptom,
plus combinations with epigastric pain. Indeed, there must be
considerable overlap between these two symptoms, with many
clinicians using them interchangeably (we assigned these symp-
toms according to the GP’s records, but each GP will have their
own personal definition of the two terms).
By lowering the threshold for investigation, many more
patients would be identified (as dyspepsia, in particular, was
common in cases). This would bring considerable investigative
costs. Until prevention by reduction of alcohol, smoking or obesity
reduces the incidence – and this is not likely in the short term – or
a screening programme is developed – and again it is difficult to
conceive of what this could be – or a biomarker is uncovered, then
the only solution to the UK marked excess mortality from
oesophago-gastric cancer will be a considerable expansion of
testing. Currently, there is almost a threefold variation within
England, with European rates even higher (Department of Health,
2012).This will mean commissioners and clinicians accepting the
financial and organisational costs, as well as patients accepting a
high initial ‘false-positive rate’ – that is, being selected for
endoscopy, yet transpiring not to have cancer. This is not our
decision as authors to make, though our research shows that it is
naive to believe that more appropriate selection of patients will
identify a higher number of cancers without increasing use of
investigations.
CONCLUSION
Although current mortality from oesophago-gastric cancer is very
high in the United Kingdom, other European countries have better
outcomes from cancer (Abdel-Rahman et al, 2009). It is not known
if these better outcomes arise from better access to investigations or
public awareness of symptoms, or both. This study has two main
uses: first, it can guide GPs in the selection of patients for urgent
investigation, and second, it suggests that selection of patients for
investigation using only alarm symptoms will have a limited effect.
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